Log in to save to my catalogue

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: re...

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: re...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6241618

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

About this item

Full title

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Publisher

England: Elsevier Limited

Journal title

Annals of the rheumatic diseases, 2018-12, Vol.77 (12), p.1710-1719

Language

English

Formats

Publication information

Publisher

England: Elsevier Limited

More information

Scope and Contents

Contents

ObjectivesTo evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA).MethodsPatients (2–19 years) entered two phase III studies and continued in the long-term extension (LTE) study. Efficacy assessments were performed every 3 months, including adapted JIA American College of Rhe...

Alternative Titles

Full title

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6241618

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6241618

Other Identifiers

ISSN

0003-4967

E-ISSN

1468-2060

DOI

10.1136/annrheumdis-2018-213150

How to access this item